CGP-7930

CGP-7930 was the first positive allosteric modulator of GABAB receptors described in literature. CGP7930 is also a GABAA receptor positive allosteric modulator and a blocker of Potassium channels.

CGP7930 was developed in Novartis and has been used extensively for scientific research. It has anxiolytic effects in animal studies, and has a synergistic effect with GABAB agonists such as baclofen and GHB,  as well as reducing self-administration of alcoholic drinks and cocaine.